Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The evolving role of alemtuzumab in management of patients with CLL LEUKEMIA Faderl, S., Coutre, S., Byrd, J. C., Dearden, C., Denes, A., Dyer, M. J., Gregory, S. A., Gribben, J. G., Hillmen, P., Keating, M., Rosen, S., Venugopal, P., Rai, K. 2005; 19 (12): 2147-2152

Abstract

New insights into prognostic markers and the pathophysiology of chronic lymphocytic leukemia (CLL) are beginning to change the concept of CLL treatment. Alemtuzumab has evolved as a potent and effective therapeutic option for patients with CLL. Specifically, alemtuzumab has demonstrated substantial efficacy in fludarabine-refractory patients and has shown impressive responses when administered subcutaneously in first-line therapy. A group of experts gathered to discuss new data related to the use of alemtuzumab in CLL and to assess its place in the rapidly changing approach to treating patients with this disease. The main goals of this program were to update the management guidelines that were previously developed for alemtuzumab-treated patients and to provide community oncologists with guidance on the most effective way to integrate alemtuzumab into a CLL treatment plan.

View details for DOI 10.1038/sj.leu.2403984

View details for Web of Science ID 000233462300015

View details for PubMedID 16239912